Retrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib Inhibitors or Anti-VEGF Antibody -Inhibiteurs mTOR - Axitinib
NCT03129724 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2017-04-26
Summary
Describe in patients with metastatic kidney cancer treatment modalities with the type sequences: TKI - mTORi - Axitinib or VEGF mAb - mTORi - Axitinib.
Conditions
- Kidney Neoplasms
Sponsors & Collaborators
-
University Hospital, Strasbourg, France
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-09-30
- Primary Completion
- 2017-07-31
- Completion
- 2017-07-31
More Related Trials
-
Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents
NCT03185039 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
"Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC"
NCT03538717 ·Status: COMPLETED
-
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma
NCT04698213 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer
NCT01255137 ·Status: COMPLETED ·Phase: PHASE2
-
Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors
NCT02700568 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN)
NCT02597322 ·Status: COMPLETED ·Phase: PHASE2
-
CARE1 Pragmatic Clinical Trial
NCT06364631 ·Status: RECRUITING ·Phase: PHASE3
-
Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer
NCT04823923 ·Status: RECRUITING ·Phase: NA
-
Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)
NCT00569946 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
NCT04033991 ·Status: COMPLETED
-
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
NCT05805501 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer
NCT02002312 ·Status: COMPLETED ·Phase: PHASE2
-
Retrospective Study on the Safety of Nivolumab in Patients With mRCC and Renal Failure
NCT07117409 ·Status: TERMINATED
-
Retrospective Observational Study To Update 5-Year Survival Of Subjects Who Participated In Axitinib Trial A4061012
NCT01056263 ·Status: COMPLETED
-
RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib
NCT00410124 ·Status: COMPLETED ·Phase: PHASE3
-
Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma
NCT02489695 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
NCT02639182 ·Status: COMPLETED ·Phase: PHASE2
-
Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic Therapy
NCT06882486 ·Status: RECRUITING ·Phase: NA
-
Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer
NCT00835978 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment
NCT01473043 ·Status: NO_LONGER_AVAILABLE
-
A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer
NCT00715182 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread
NCT04540705 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy
NCT01693822 ·Status: COMPLETED ·Phase: PHASE2
-
Primary Metastatic Renal Cell Carcinoma Treated With Immunecheckpoint Inhibitors and Cytoreductive Nephrectomy
NCT05941169 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
NCT00378703 ·Status: COMPLETED ·Phase: PHASE2